Clinical trials: Positive Axillary Lymph Node, active
Breast Cancer, Chemotherapy
ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer
In the case of primary surgery, in patients with sentinel node involvement, it has already been shown that omitting axillary lymph node dissection (ALND), often combining axillary radiotherapy (RT), does not worsen the prognosis…
- Conditions
- Breast Cancer, Chemotherapy, Sentinel Lymph Node, Axillary Lymph Nodes Dissection
- Trial name
- ADARNAT (NCT04889924)
- Testing
- Axillary Radiotherapy, Lymphadenectomy
- Where
- 61 sites in Australia, Spain
- Volunteers
- 820 people
- Sponsor
- Hospital Universitari de Bellvitge
Breast Cancer
Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast Cancer
The goal of this clinical trial is to evaluate the safety and feasibility of methylene blue single tracer-based extensive sentinel lymph node biopsy (ESLNB) and provide evidence for simplifying surgical procedures on the basis of…
- Trial name
- NCT07532096
- Testing
- ESLNB
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Xijing Hospital
Breast Cancer, Radiotherapy; Complications
Medial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer
Locally advanced breast cancer has high-risk local regional recurrence after surgery. Radiotherapy could reduce the local regional recurrence and improve disease free survival and overall survival.
- Conditions
- Breast Cancer, Radiotherapy; Complications, Effect of Radiation Therapy
- Trial name
- SUCLANODE (NCT05059379)
- Testing
- Entire supraclavicular lymph node radiotherapy, Medial supraclavicular lymph node radiotherapy
- Where
- China
- Volunteers
- 1,650 people
- Sponsor
- Fudan University
Breast Carcinoma Metastatic in Lymph Node, HER2 Positive Breast Carcinoma
Validation of TAD in HER-2 with More Than 2 Lymph Nodes
The main objective of the study is to validate the DAT technique in patients with Her2-positive breast cancer who have more than two positive axillary lymph nodes at diagnosis.
- Trial name
- DAD-HER2 (NCT06821490)
- Testing
- Targeted axillary dissection and subsequently a lymphadenectomy
- Where
- Spain
- Volunteers
- 21 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Breast Cancer Female, Breast Cancer, Male
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
The main purpose of this study is to evaluate the safety of each study vaccine and to evaluate the effect on the time to disease recurrence (assessed by disease free survival).
- Conditions
- Breast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I, Breast Cancer Stage II
- Trial name
- NCT03384914
- Testing
- DC1 Vaccine, WOKVAC Vaccine
- Where
- 7 sites in United States
- Volunteers
- 119 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer
Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple Negative Breast Cancer: The OPBC-11/MACRONAC Study
In this multicenter retrospective cohort study the aim is to determine the safety of omission of axillary lymph node dissection in patients with TNBC and HER2+ tumors with residual macrometastases (in the SLN/TAD/TAS or MARI…
- Trial name
- MACRONAC (NCT07546695)
- Testing
- Data Collection from medical records of from an already existing database "ONCOLOGICAL BREAST SURGERY DATABASE OF THE UNIVERSITY HOSPITAL OF BASEL" which was initiated in 2016.
- Where
- Switzerland
- Volunteers
- 600 people
- Sponsor
- University Hospital, Basel, Switzerland
Breast Cancer
POSNOC - A Trial Looking at Axillary Treatment in Early Breast Cancer
POSNOC is a pragmatic, randomised, multicentre, non-inferiority trial. Aim For women with early stage breast cancer and one or two sentinel node macrometastases, to assess whether adjuvant therapy alone is no worse than adjuvant…
- Trial name
- POSNOC (NCT02401685)
- Testing
- Adjuvant therapy, Axillary treatment
- Where
- 50 sites in Australia, New Zealand and 1 more
- Volunteers
- 1,900 people
- Sponsor
- University Hospitals of Derby and Burton NHS Foundation Trust
BREAST CANCER, PET/CT
68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
The goal of this observational study is to learn whether 68Ga-FAPI PET/CT may be used as a new effective methods for evaluating axillary lymph node efficacy after neoadjuvant treatment for breast cancer.
- Trial name
- NCT06559371
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Kunwei Shen
Breast Cancer Female, Early-stage Breast Cancer
Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer
RATIONALE: It is now standard for most breast cancer patients with 1-2 positive sentinel nodes to avoid completion node dissection when eligibility criteria from the American College of Surgeons Oncology Group (ACOSOG) Z0011…
- Conditions
- Breast Cancer Female, Early-stage Breast Cancer, Lymph Node Metastases, Axillary Metastases
- Trial name
- TADEN (NCT04671511)
- Testing
- Targeted Axillary Dissection, Ultrasound of the axilla
- Where
- 3 sites in Canada
- Volunteers
- 98 people
- Sponsor
- Jewish General Hospital
Breast Cancer, Axillary Lymph Nodes
Using LUminoMark vs Coventional Practice for Targeted Axillary Surgery
The purpose of this study was to compare the use of LuminoMarkTM as a method of targeting axillary lymph nodes with other existing methods used in each institution, such as charcoal staining, needle targeting, and…
- Conditions
- Breast Cancer, Axillary Lymph Nodes, Target Lesion
- Trial name
- LUCAS (NCT06903429)
- Testing
- Targeting of axillary lymph nodes using LuminoMark, Targeting of axillary lymph nodes using conventional method
- Volunteers
- 330 people
- Sponsor
- Kyungpook National University Chilgok Hospital
Breast Cancer
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
This trial is to investigate if in patients with clinically node positive breast cancer undergoing upfront surgery, treatment with TAS and ART is superior to ALND in terms of arm-related Quality of Life (QoL) and occurrence of…
- Trial name
- OPBC-10/ NOAX (NCT07140172)
- Testing
- Axillary lymph node dissection (ALND), Axillary radiotherapy (ART)
- Where
- 55 sites in United States, Austria and 9 more
- Volunteers
- 1,060 people
- Sponsor
- University Hospital, Basel, Switzerland
Breast Cancer by AJCC V8 Anatomic Stage, Breast Cancer
De-escalation of Axillary Dissection for Node-positive Breast Cancer
Recent studies have demonstrated the safety of de-escalation of nodal surgery for clinically node-positive breast cancer patients after a favorable response to neoadjuvant systemic therapy (NST).
- Trial name
- NCT07856160
- Testing
- TAD, ALND
- Volunteers
- 20 people
- Sponsor
- University of Nebraska
Breast Cancer, Axillary Lymph Nodes Dissection
Audit of Targeted Sentinel Node Biopsy (TSNB) in Patients With Limited Nodal Disease Undergoing Primary Surgery
Axillary ultrasound scan (AUS) is routinely employed in the UK for preoperative axillary staging and can diagnose approximately 50 - 80% of node positive patients when combined with percutaneous needle biopsy techniques (either…
- Conditions
- Breast Cancer, Axillary Lymph Nodes Dissection, Axillary Metastases, Sentinel Lymph Node Biopsy (SLNB)
- Trial name
- NodeSMART (NCT07085442)
- Testing
- Targeted Sentinel Node Biopsy (TSNB)
- Where
- 14 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- University Hospitals of Derby and Burton NHS Foundation Trust
Breast Cancer, Surgery
Targeted Resection of Axillary Metastatic Lymph Nodes After Breast Cancer Neoadjuvant Chemotherapy
This study evaluates the efficacy and feasibility of Carbon Nanoparticle Suspension Injection (CNSI) for Targeted Axillary Dissection (TAD) in breast cancer patients undergoing neoadjuvant chemotherapy (NAC), compared to…
- Conditions
- Breast Cancer, Surgery, Lymph Node Metastases
- Trial name
- NCT04744506
- Testing
- Tissue Marker Clip, Carbon Nanoparticle Suspension Injection
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer
AXillary Surgery After NeoAdjuvant Treatment
The optimal surgical axillary staging technique in patients who convert from the clinically positive to clinically negative lymph node status under neoadjuvant therapy (cN+ → ycN0) remains to be clarified.
- Trial name
- AXSANA (NCT04373655)
- Where
- Germany
- Volunteers
- 3,000 people
- Sponsor
- European Breast Cancer Research Association of Surgical Trialists
Node-positive Breast Cancer
Axillary Node Dissection w or w/o LVB in Node Positive Breast Cancer Patients
Lymphedema is a devastating complication of breast cancer surgery that decreases the quality of life of up to 40% of breast cancer survivors.
- Trial name
- NCT05970107
- Testing
- Axillary Lymph Node Dissection, Axillary Reverse Mapping, Lymphaticovenous Bypass
- Volunteers
- 400 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer, Node-positive Breast Cancer
TAD in Primary Breast Cancer With Initially ≥ 3 Suspicious Lymph Nodes
Due to high pathological complete remission (pCR) rates in both breast and lymph nodes (ypT0/Tis, ypN0) following neoadjuvant systemic therapy (NST) in many patients with initially clinically node-positive (cN+) breast cancer…
- Trial name
- SenTa2 (NCT05462457)
- Testing
- Targeted axilllary dissection (TAD) followed by axillary lymph node dissection (ALND)
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Kliniken Essen-Mitte
Invasive Breast Cancer
Axillary Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node
Data from cohorts, prospective studies and one randomized trial (ASCOG Z0011) support the hypothesis that omission of additional axillary dissection in case of positive sentinel node has a limited impact on overall survival and…
- Trial name
- NCT01717131
- Testing
- Surgery for standard axillary node dissection, No axillary lymph node dissection
- Where
- France
- Volunteers
- 2,228 people
- Sponsor
- Institut Paoli-Calmettes
Breast Cancer
Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm (ASLAN) Study
The aims of this study is to evaluate 5 year recurrence free survival when omit sentinel lymph node biopsy after neoadjuvant chemotherapy in triple negative or HER-2 positive breast cancer patients when physical examination…
- Trial name
- ASLAN (NCT04993625)
- Testing
- avoid axillary sentinel lymph node biopsy after neoadjuvant chemotherapy
- Where
- South Korea
- Volunteers
- 178 people
- Sponsor
- Jeong Eon Lee
Breast Cancer
Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial.
Since the introduction of sentinel node biopsy in breast cancer, it has become clear that its use is reliable and reproducible. Today, it is clinical routine to not remove further lymph nodes from the axilla (arm pit) in case the…
- Trial name
- NCT02240472
- Testing
- Omission of axillary clearance
- Where
- 33 sites in Denmark, Greece and 1 more
- Volunteers
- 2,766 people
- Sponsor
- Karolinska Institutet